Sean Brynjelsen - Jun 3, 2025 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
President & CEO, Director, 10%+ Owner
Signature
/s/ James R. Gruber
Stock symbol
ETON
Transactions as of
Jun 3, 2025
Transactions value $
-$3,592,611
Form type
4
Date filed
6/5/2025, 05:15 PM
Previous filing
Jan 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BRYNJELSEN SEAN President & CEO, Director, 10%+ Owner C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK /s/ James R. Gruber 2025-06-05 0001669976

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETON Common Stock Sale -$1.06M -60.9K -1.98% $17.38 3.02M Jun 3, 2025 Direct F1, F6
transaction ETON Common Stock Sale -$159K -8.66K -0.29% $18.38 3.01M Jun 3, 2025 Direct F2, F6
transaction ETON Common Stock Sale -$7.61K -400 -0.01% $19.02 3.01M Jun 3, 2025 Direct F3, F6
transaction ETON Common Stock Sale -$1.19M -70K -2.32% $17.00 2.94M Jun 4, 2025 Direct F4, F6
transaction ETON Common Stock Sale -$1.18M -70K -2.38% $16.81 2.87M Jun 5, 2025 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold in multiple trades at prices ranging from $17.00 to $17.88. The price reported above reflects the weighted average sales price.
F2 The shares were sold in multiple trades at prices ranging from $18.15 to $18.85. The price reported above reflects the weighted average sales price.
F3 The shares were sold in multiple trades at a price of $19.02.
F4 The shares were sold in multiple trades at prices ranging from $16.86 to $17.20. The price reported above reflects the weighted average sales price.
F5 The shares were sold in multiple trades at prices ranging from $16.62 to $17.15. The price reported above reflects the weighted average sales price.
F6 The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.